Skip to main content

Table 1 Patient characteristics

From: Childhood Pompe disease: clinical spectrum and genotype in 31 patients

Pt

Sex

Onset (y)g

Diagnosis (y)g

Examination (y)g

Wheelchair (y)

Ventilator (y)

FVC z-score sitting (% pred)

FVC z-score supine (% pred)

MRC %

CK U/l

GAA activity (nmol/h/mg)h

Allele 1

Allele 2

1a

M

0.5

2.5

10.04

Yes (11)

No

–0.25 (97 %)

–1.12 (87 %)

65 %

530

9.1

c.-32–13T > G (pm)

c.525delT (vs)

2e, f

F

0.8

0

0.1

No

No

Too young

Too young

n.a.

358

Deficient

c.-32–13T > G (pm)

c.2135 T > C (ls)

3

F

0.8

1.1

8.9

No

No

0.21 (102 %)

0.1 (101 %)

89 %

1871

13.3

c.-32–13T > G (pm)

c.923A > C (pls)

4e

M

0.8

2

2.4

No

No

Too young

Too young

n.a.

1353

13

c.-32–13T > G (pm)

c.2135 T > C (ls)

5

M

0.8

2.3

9.5

No

No

–1.53 (82 %)

–1.71 (80 %)

98 %

550

15.4

c.-32–13T > G (pm)

c.525delT (vs)

6

M

1

2

8.2

Partially (4)

No

–3.47 (59 %)

–4.36 (48 %)

79 %

3078

4.5

c.-32–13T > G (pm)

c.1051delG (vs)

7

M

1

2

13.7

No

At night (12)

–4.08 (54 %)

–5.4 (39 %)

87 %

548

17.9

c.-32–13T > G (pm)

c.525delT (vs)

8

M

1.5

2

13.3

No

No

–0.91 (90 %)

–1.76 (80 %)

93 %

1595

16

c.-32–13T > G (pm)

c.2481 + 102_2646 + 31del (vs)

9a, f

M

2

1

6.6

No

No

–0.97 (89 %)

–1.4 (84 %)

94 %

763

11

c.-32–13T > G (pm)

c.525delT (vs)

10

M

2.5

3

13

No

No

–3.01 (66 %)

–4.09 (54 %)

84 %

1960

8.6

c.-32–13T > G (pm)

c.2331 + 2 T > A (vs)

11d

M

5

10.8

10.8

No

No

0.2 (102 %)

–0.29 (97 %)

97 %

588

11.9

c.-32–13T > G (pm)

c.525delT (vs)

12

F

5

7.8

7.8

No

No

0.62 (108 %)

0.35 (104 %)

100 %

1003

11.6

c.-32–13T > G (pm)

c.2331 + 2 T > A (vs)

13f

M

5

2

7.6

No

At night (5)

–1.77 (78 %)

–1.72 (79 %)

100 %

436

Deficient

c.-32–13T > G (pm)

c.1062C > G (pls)

14

M

7

10

10.7

Yes (22)

At night (16)

–2.22 (75 %)

Unable

80 %

540

8,9

c.-32–13T > G (pm)

c.1548G > A (pls)

15f

M

8

4

15.8

No

No

–2.65 (70 %)

–3.05 (65 %)

93 %

1424

7.8

c.-32–13T > G (pm)

c.1441 T > C (pls)

16f

M

12

8

14.6

No

No

–2.43 (71 %)

Unable

82 %

1808

Deficient

c.-32–13T > G (pm)

c.307 T > G + c.271G > A (pls)

17

M

13

14

14.3

No

No

–1.68 (81 %)

–1.77 (80 %)

95 %

2935

6.2

c.-32–13T > G (pm)

c.1933G > A (pls)

18f

M

no symptoms

4

5.2

No

No

–1.41 (82 %)

–1.96 (76 %)

97 %

677

Deficient

c.-32–13T > G (pm)

c.2481 + 102_2646 + 31del (vs)

19d, f

M

no symptoms

13.1

13.1

No

No

–0.69 (92 %)

–1.77 (80 %)

100 %

614

Deficient

c.-32–13T > G (pm)

c.525delT (vs)

20c, f

M

no symptoms

14

15.2

No

No

3 (135 %)

1.72 (120 %)

n.a.

1409

Deficient

c.-32–13T > G (pm)

c.307 T > G (pls)

21c, f

M

no symptoms

16

17.1

No

No

1.29 (115 %)

–0.25 (97 %)

n.a.

1506

Deficient

c.-32–13T > G (pm)

c.307 T > G (pls)

22

M

0.5

1

1.3

Yes (4)

Died (10)i

–4.77 (45 %)j

Unable

n.a.

586

Deficient

c.1798C > T (ls)

c.525delT (vs)

23

F

1

1.9

12.5

Yes (6)

Yes (6)

Ventilator

Ventilator

10 %

1381

Deficient

c.875A > G (pm)

unknown/r.0?

24

M

2

2.9

2.9

Yes (6)

Died (6)i

–5.29 (33 %)j

Unable

n.a.

1046

Deficient

unknown

c.1645G > A (pm)

25

M

2.7

3.5

5.9

No

No

0.34 (104 %)

0.04 (100 %)

87 %

908

2.8

c.1634C > T (ls)

c.2481 + 102_2646 + 31del (vs)

26b

F

4

4

8.1

No

No

0.01 (100 %)

–0.63 (92 %)

98 %

572

2.3

c.-32–3C > G (ls)

c.1551 + 1G > A (vs)

27b

M

5

5

10.1

No

No

–1.38 (84 %)

–2.55 (71 %)

n.a.

774

1.7

c.-32–3C > G (ls)

c.1551 + 1G > A (vs)

28

F

6

7

9.9

Partially (9)

At night (8)

–6.36 (30 %)

–6.88 (25 %)

82 %

979

0.3

c.1829C > T (ls)

c.1912G > T (pls)

29

F

6.5

11.6

12.7

No

No

–2.36 (73 %)

–2.89 (67 %)

79 %

776

8.4

unknown (r.spl 2 %)

c.525delT (vs)

30

F

10

11

16.4

Yes (16)

Yes (12)

–8.07 (13 %)

Unable

72 %

1560

3.4

c.-32–3C > A (ls)

c.877G > S + c.271G > A (pls)

31f

F

no symptoms

15

15.9

No

No

1.33 (116 %)

1.2 (115 %)

100 %

1040

2.5

c.861C > T (r.spl = <5 %)

c.925G > A (pls)

  1. Patients are listed by age of onset and are subdivided into two groups: those who carry the c.-32–13T > G mutation and those who do not a, b, c, d, e : Siblings; f patients who were diagnosed pre-symptomatically; g: Age at onset, age at diagnosis, age at examination expressed in years (y); h: GAA activity was deficient in all patients. Only results obtained in cultured fibroblasts and performed with the same method at Erasmus MC are reported; i: both patients died of respiratory failure, one at age 6, the other at age 10; j: first available lung function measurement (patient still untreated) at the ages of respectively 9 and 5.7 years; severity of the mutation is indicated by (vs) very severe; (pls) potentially less severe; (ls) less severe; (pm) potentially mild (for more information, see www.pompecenter.nl)